Atrial natriuretic peptide secretion was not directly affected by arginine vasopressin in diabetes insipidus. 1991

H Shimizu, and Y Tanaka, and K Nakamura, and Y Uehara, and Y Shimomura
First Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.

A 42-year-old woman was admitted to our hospital because of polydipsia and polyuria. On admission, the daily urine volume was about 6 to 8 L/day, and the plasma arginine vasopressin (AVP) level was undetectable. To determine an involvement of atrial natriuretic peptide (ANP) in maintaining plasma volume homeostasis in the patient with diabetes insipidus (DI), changes of plasma ANP levels were measured during the daytime and after 2.5% hypertonic saline followed by intravenous administration of Pitressin. The plasma ANP level was maintained within a normal range during the day. An intravenous infusion of 2.5% hypertonic saline increased plasma ANP levels, while it failed to increase urine osmolality. The addition of an intravenous bolus of Pitressin (10 U) increased urine osmolality with a decrease of urine volume. Plasma ANP levels showed only a transient decrease at 15 min after Pitressin injection. A daily supplement of 1-desamino-8-D-arginine vasopressin (DDAVP) slightly decreased plasma ANP levels. The present study suggests that an increase in plasma AVP level may not have a direct stimulatory action on ANP secretion in patients with DI.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009320 Atrial Natriuretic Factor A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. ANF,ANP,Atrial Natriuretic Peptide,Atrial Natriuretic Peptides,Atriopeptins,Auriculin,Natriuretic Peptides, Atrial,ANF (1-126),ANF (1-28),ANF (99-126),ANF Precursors,ANP (1-126),ANP (1-28),ANP Prohormone (99-126),ANP-(99-126),Atrial Natriuretic Factor (1-126),Atrial Natriuretic Factor (1-28),Atrial Natriuretic Factor (99-126),Atrial Natriuretic Factor Precursors,Atrial Natriuretic Factor Prohormone,Atrial Natriuretic Peptide (1-126),Atrial Pronatriodilatin,Atriopeptigen,Atriopeptin (1-28),Atriopeptin (99-126),Atriopeptin 126,Atriopeptin Prohormone (1-126),Cardiodilatin (99-126),Cardiodilatin Precursor,Cardionatrin I,Cardionatrin IV,Prepro-ANP,Prepro-CDD-ANF,Prepro-Cardiodilatin-Atrial Natriuretic Factor,Pro-ANF,ProANF,Proatrial Natriuretic Factor,Pronatriodilatin,alpha ANP,alpha-ANP Dimer,alpha-Atrial Natriuretic Peptide,beta-ANP,beta-Atrial Natriuretic Peptide,gamma ANP (99-126),gamma-Atrial Natriuretic Peptide,Natriuretic Peptide, Atrial,Peptide, Atrial Natriuretic,Peptides, Atrial Natriuretic,Prepro ANP,Prepro CDD ANF,Prepro Cardiodilatin Atrial Natriuretic Factor,Pro ANF,alpha ANP Dimer,alpha Atrial Natriuretic Peptide,beta ANP,beta Atrial Natriuretic Peptide,gamma Atrial Natriuretic Peptide
D010953 Plasma Volume Volume of PLASMA in the circulation. It is usually measured by INDICATOR DILUTION TECHNIQUES. Blood Plasma Volume,Blood Plasma Volumes,Plasma Volumes,Volume, Blood Plasma,Volume, Plasma,Volumes, Blood Plasma,Volumes, Plasma
D003894 Deamino Arginine Vasopressin A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR. Desmopressin,Vasopressin, Deamino Arginine,1-Deamino-8-D-arginine Vasopressin,1-Desamino-8-arginine Vasopressin,Adiuretin,Adiuretin SD,Apo-Desmopressin,DDAVP,Desmogalen,Desmopressin Acetate,Desmopressin Monoacetate,Desmopressin Monoacetate, Trihydrate,Desmopressine Ferring,Desmospray,Desmotabs,Minirin,Minurin,Nocutil,Octim,Octostim,Acetate, Desmopressin,Arginine Vasopressin, Deamino,Ferring, Desmopressine,Monoacetate, Desmopressin,Monoacetate, Trihydrate Desmopressin,Trihydrate Desmopressin Monoacetate,Vasopressin, 1-Deamino-8-D-arginine,Vasopressin, 1-Desamino-8-arginine
D003919 Diabetes Insipidus A disease that is characterized by frequent urination, excretion of large amounts of dilute URINE, and excessive THIRST. Etiologies of diabetes insipidus include deficiency of antidiuretic hormone (also known as ADH or VASOPRESSIN) secreted by the NEUROHYPOPHYSIS, impaired KIDNEY response to ADH, and impaired hypothalamic regulation of thirst.
D005260 Female Females
D006706 Homeostasis The processes whereby the internal environment of an organism tends to remain balanced and stable. Autoregulation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001127 Arginine Vasopressin The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. Argipressin,Vasopressin, Arginine,Arg-Vasopressin,Argipressin Tannate,Arg Vasopressin

Related Publications

H Shimizu, and Y Tanaka, and K Nakamura, and Y Uehara, and Y Shimomura
August 1993, Acta psychiatrica Scandinavica,
H Shimizu, and Y Tanaka, and K Nakamura, and Y Uehara, and Y Shimomura
March 2011, American journal of physiology. Regulatory, integrative and comparative physiology,
H Shimizu, and Y Tanaka, and K Nakamura, and Y Uehara, and Y Shimomura
March 1989, The American journal of physiology,
H Shimizu, and Y Tanaka, and K Nakamura, and Y Uehara, and Y Shimomura
February 1988, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
H Shimizu, and Y Tanaka, and K Nakamura, and Y Uehara, and Y Shimomura
January 1998, International urology and nephrology,
H Shimizu, and Y Tanaka, and K Nakamura, and Y Uehara, and Y Shimomura
September 1992, Endocrinology,
H Shimizu, and Y Tanaka, and K Nakamura, and Y Uehara, and Y Shimomura
January 1990, Mineral and electrolyte metabolism,
H Shimizu, and Y Tanaka, and K Nakamura, and Y Uehara, and Y Shimomura
July 1988, Clinical science (London, England : 1979),
H Shimizu, and Y Tanaka, and K Nakamura, and Y Uehara, and Y Shimomura
April 1992, Pediatric research,
H Shimizu, and Y Tanaka, and K Nakamura, and Y Uehara, and Y Shimomura
May 1995, Cancer,
Copied contents to your clipboard!